Plain-English translation of NCT03449238 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether , an immunotherapy medication, works better when combined with stereotactic radiosurgery (a precise form of radiation therapy) to treat brain tumors caused by metastatic breast cancer. You would receive the radiation therapy first, then start the medication a few days later and continue it every three weeks as long as it's helping and you're tolerating it well.
Brain metastases are a serious complication of metastatic breast cancer, and current treatments don't work well for everyone. This trial is exploring whether combining radiation with immunotherapy—which helps your immune system fight cancer—might offer better outcomes than either treatment alone.
You likely qualify if…
You likely don't qualify if…
You would receive stereotactic radiosurgery (a focused radiation treatment) first, completed within one week. Then, starting around day 4, you would begin receiving the immunotherapy medication as an intravenous infusion (given through an IV) that takes about 30 minutes, repeated every 3 weeks. You would continue this treatment until either your brain tumors start growing again or you experience side effects that are too severe to continue. Throughout the trial, you'll have regular follow-up appointments and imaging scans to monitor how you're responding.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States